Notes
The patients, suspects and toxicities were captured from table 1 of the article (available on online link).
Reference
Eyre TA, et al. Idelalisib-rituximab results in considerable toxicity but induces durable clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukemia. Blood 130 (Suppl. 1): abstr. 4068, 2017. Available from: URL: http://www.bloodjournal.org/content/130/Suppl_1/4068?sso-checked=true [abstract] -United Kingdom
Rights and permissions
About this article
Cite this article
Idelalisib/rituximab. Reactions Weekly 1695, 208 (2018). https://doi.org/10.1007/s40278-018-44035-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-44035-1